Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by StockNews.com

StockNews.com began coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research note released on Sunday morning. The brokerage issued a hold rating on the stock.

Other analysts have also issued reports about the company. HC Wainwright cut their price target on Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. Brookline Capital Management reissued a “hold” rating on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. Northland Capmk lowered Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 12th. Finally, Northland Securities restated a “market perform” rating and set a $2.00 price objective on shares of Oncternal Therapeutics in a research report on Thursday, September 12th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $20.00.

Oncternal Therapeutics Trading Up 6.2 %

NASDAQ ONCT opened at $1.72 on Friday. The company has a market cap of $5.09 million, a PE ratio of -0.14 and a beta of 1.33. Oncternal Therapeutics has a 12 month low of $1.05 and a 12 month high of $13.14. The stock has a 50 day moving average of $2.02 and a 200-day moving average of $5.52.

Oncternal Therapeutics (NASDAQ:ONCT) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($2.89) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.03) by $0.14. The business had revenue of $0.80 million for the quarter, compared to analysts’ expectations of $0.24 million. Oncternal Therapeutics had a negative return on equity of 136.10% and a negative net margin of 1,948.70%. During the same quarter in the prior year, the business earned ($3.00) EPS. As a group, sell-side analysts predict that Oncternal Therapeutics will post -12.43 EPS for the current fiscal year.

Institutional Investors Weigh In On Oncternal Therapeutics

A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Pasadena Private Wealth LLC bought a new stake in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned about 0.84% of Oncternal Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 16.05% of the company’s stock.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.